919347-16-3

Basic information

• Product Name: 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine
• Synonyms: 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine;4-[[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methyl]morpholine
• CAS NO: 919347-16-3
• Molecular Formula: C₁₆H₂₅BN₂O₃
• Molecular Weight: 304
• Mol File: 919347-16-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine(919347-16-3)
• EPA Substance Registry System: 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine(919347-16-3)

Safety Data

• Hazardous Substances Data: 919347-16-3(Hazardous Substances Data)

Usage

Uses

Used in Coordination Chemistry:
4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine is used as a ligand in coordination chemistry for its ability to bind with metal ions, facilitating the formation of stable metal complexes that can be utilized in catalysis and other applications.
Used in Organic Synthesis:
In the field of organic synthesis, 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine is used as a building block for constructing more complex organic molecules. Its boron-containing functional group allows it to participate in various chemical reactions, such as cross-coupling reactions, which are essential for the synthesis of pharmaceuticals and other organic compounds.
Used in Metal-Catalyzed Reactions:
4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine is used as a ligand in metal-catalyzed reactions to enhance the efficiency and selectivity of these processes. Its presence can modulate the reactivity and stability of metal catalysts, leading to improved outcomes in organic transformations.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine may be used as an intermediate in the synthesis of drug candidates. Its unique structural features can be exploited to create novel compounds with potential therapeutic properties.
Used in Material Science:
4-((5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methyl)morpholine can be used in material science for the development of new materials with specific properties. Its ability to form stable complexes with metal ions may contribute to the creation of materials with tailored characteristics for various applications, such as sensors, catalysts, or advanced materials with unique electronic or optical properties.

Upstream product

• 342013-81-4 4-[(5-bromopyridin-3-yl)carbonyl]morpholine 
• 364793-91-9 4-((5-bromopyridin-3-yl)methyl)morpholine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

The present invention relates to the 1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS

Provided are compounds according to Formula (I), or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R1, R6 , R7, and R8 are as defined, which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PB -kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

CHEMICAL COMPOUNDS

The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula I: where R1, R2, R3, U and V are defined below and to pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.